Cannabis and Crohn's Disease: What Gastroenterology Research Shows

Gut / Digestion

Feels Better ≠ Healed

The Naftali 2021 RCT showed cannabis improved Crohn's symptoms and quality of life, but endoscopy revealed no mucosal healing, meaning patients can feel better while inflammation silently continues.

Naftali et al., Clinical Gastroenterology and Hepatology, 2021

Naftali et al., Clinical Gastroenterology and Hepatology, 2021

View as image

Crohn's disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, from mouth to anus, though it most commonly involves the terminal ileum and colon. Unlike IBS, which is a functional disorder, Crohn's involves visible, measurable inflammation that causes tissue damage. Left untreated, it leads to strictures, fistulas, abscesses, and the need for surgical resection.

The standard of care for Crohn's disease has evolved significantly over the past two decades. Biologic medications, including anti-TNF agents (infliximab, adalimumab), vedolizumab, and ustekinumab, have transformed outcomes for many patients. Small molecule therapies like tofacitinib and upadacitinib offer additional options. The treatment goal has shifted from symptom control to mucosal healing, meaning the actual resolution of inflammation visible on endoscopy.

Cannabis enters this landscape as a treatment that patients are already using in substantial numbers. Surveys consistently show that 15 to 40 percent of IBD patients use or have used cannabis for symptom management. The question is not whether patients are using it. The question is what the evidence shows about what it does and does not do.

The Naftali Trials: Landmark Evidence

Gut / Digestion

Cannabis & Crohn's: The Naftali Trial Evidence

Naftali 2013

Design: RCT, 21 patients, THC cigarettes vs placebo

Result: 10/11 cannabis vs 4/10 placebo achieved clinical response

Mucosal healing: Not measured

Naftali 2021

Design: RCT, 56 patients, THC+CBD oil vs placebo

Result: Significant symptom improvement + quality of life gains

Mucosal healing: No — endoscopy showed no difference vs placebo

The Critical Distinction

Feeling better (symptoms)Consistently improved in trialsImportant for quality of life

Being better (mucosal healing)Not achieved in any trialCritical — uncontrolled inflammation keeps damaging bowel silently

Do not stop biologics/DMARDs • Avoid smoking route • Not medical adviceCannabis and Crohn's Trial Evidence

The most important clinical evidence for cannabis and Crohn's comes from a series of studies conducted by Timna Naftali and colleagues at Meir Medical Center in Israel.

Naftali 2013: This randomized, placebo-controlled trial enrolled 21 patients with active Crohn's disease who had not responded to conventional treatment. Patients received either cannabis cigarettes containing 115 mg THC or placebo cigarettes for 8 weeks. The results showed a significant clinical response in 10 of 11 patients in the cannabis group compared to 4 of 10 in the placebo group. Complete remission was achieved in 5 of 11 cannabis patients versus 1 of 10 placebo patients. Three patients in the cannabis group were able to discontinue steroids.

The improvements were primarily in symptoms: abdominal pain, appetite, and overall well-being. This was a meaningful result for patients whose symptoms had not responded to other treatments.

Naftali 2021: This follow-up study was larger and more methodologically rigorous. It was a randomized, double-blind, placebo-controlled trial of cannabis oil (containing both THC and CBD) in 56 Crohn's patients with mild to moderate disease activity. The study measured both clinical outcomes and endoscopic outcomes.

The results were nuanced. Cannabis improved clinical symptoms, quality of life, and Crohn's Disease Activity Index scores compared to placebo. But endoscopic assessment showed no significant improvement in mucosal healing. Patients felt better, but their gut inflammation was not meaningfully reduced as measured by the objective gold standard.

This finding is arguably the most important data point in the entire cannabis-IBD literature. It establishes that cannabis can improve how patients with Crohn's disease feel without resolving the underlying inflammation that drives disease progression.

Symptoms vs. Mucosal Healing: Why the Distinction Matters

In modern gastroenterology, mucosal healing has become the primary treatment target for Crohn's disease because it correlates with long-term outcomes. Patients who achieve mucosal healing have lower rates of hospitalization, surgery, and disease complications. Patients who achieve symptom control without mucosal healing may feel well in the short term but remain at risk for progressive bowel damage.

This creates a specific concern about cannabis in Crohn's disease. If cannabis makes patients feel significantly better without addressing the underlying inflammation, several problems can arise.

Patients may perceive their disease as controlled and become less adherent to medications that actually achieve mucosal healing. A patient who feels well on cannabis might be tempted to reduce or stop their biologic medication, not realizing that inflammation is continuing to damage their bowel.

Clinicians may not escalate treatment appropriately if patients report feeling well. If symptom scores improve on cannabis, the clinical signal to intensify anti-inflammatory therapy may be masked.

Monitoring becomes more important, not less, for Crohn's patients using cannabis. Objective markers of inflammation, including fecal calprotectin, CRP, and periodic endoscopy, should continue regardless of how patients feel.

This does not mean cannabis is harmful for Crohn's patients. It means cannabis is not a disease-modifying treatment based on current evidence, and it should not replace therapies that are.

Anti-inflammatory Mechanisms in the Gut

Despite the disappointing endoscopic results in the Naftali 2021 trial, the biological rationale for anti-inflammatory effects of cannabinoids in the gut remains strong. The gap between preclinical promise and clinical results is a common challenge in drug development.

CB2 receptors are expressed at high density on immune cells throughout the intestinal wall, including macrophages, T-cells, and dendritic cells. Activation of CB2 receptors reduces the production of pro-inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6, all of which are elevated in Crohn's disease and are targets of existing biologic therapies.

In animal models of colitis, both CB1 and CB2 agonists reduce inflammation, mucosal damage, and disease severity. CBD has shown particular promise in preclinical IBD models, reducing intestinal inflammation through mechanisms that include CB2 activation, PPARgamma agonism, and adenosine signaling.

Why these preclinical anti-inflammatory effects did not translate to mucosal healing in the Naftali 2021 trial is not entirely clear. Possible explanations include insufficient dosing, the wrong cannabinoid ratio, the short study duration (8 weeks may not be long enough for mucosal healing), or the possibility that the anti-inflammatory effects of cannabis in the gut are real but insufficient in magnitude to resolve established Crohn's inflammation.

CBD-Rich vs. THC-Rich Cannabis for IBD

The relative roles of CBD and THC in IBD are debated.

THC provides the symptom relief, including pain reduction, appetite stimulation, and improved sleep. THC also has direct anti-inflammatory properties through CB1 and CB2 activation. The Naftali 2013 trial used THC-dominant cannabis and showed clinical improvement.

CBD has broader anti-inflammatory mechanisms and does not produce intoxication. In preclinical models, CBD is at least as effective as THC for reducing gut inflammation. However, a clinical trial of CBD alone for Crohn's disease (Naftali 2017) did not show significant benefit. This trial has been criticized for using a dose that may have been too low (10 mg CBD twice daily) and for a study design that may not have captured CBD's effects.

Combination products containing both THC and CBD are the most commonly used by IBD patients and were used in the Naftali 2021 trial. The clinical improvement in that trial, despite the lack of mucosal healing, suggests that the combination provides meaningful symptom management.

The optimal ratio remains unknown. Most clinicians working with IBD patients and cannabis suggest starting with CBD-dominant products and adding THC as needed for symptom control, but this recommendation is based on clinical experience rather than comparative trial data.

Steroid-Sparing Potential

One of the most practically relevant findings from the Naftali 2013 trial was that three cannabis-treated patients were able to discontinue corticosteroids. This is meaningful because corticosteroids, while effective for inducing remission in Crohn's flares, carry significant long-term side effects: osteoporosis, diabetes, adrenal suppression, weight gain, mood disturbance, and immunosuppression.

Gastroenterologists work hard to minimize steroid exposure. Any treatment that helps patients discontinue or avoid steroids has clinical value even if it does not achieve mucosal healing on its own. If cannabis can bridge patients through flares with reduced steroid use while they are being transitioned to steroid-sparing biologics or immunomodulators, this alone would be a worthwhile contribution.

This steroid-sparing hypothesis has not been tested in a dedicated trial. It is based on the observation from the Naftali study and consistent patient reports of reduced steroid dependence. A randomized trial specifically designed to test whether cannabis reduces steroid use in Crohn's patients would be highly informative.

Quality of Life Improvements

Quality of life is not a secondary concern for Crohn's patients. The disease affects every aspect of daily life: work, relationships, social activities, diet, and mental health. Even when inflammation is controlled, many patients continue to experience fatigue, anxiety, pain, and functional limitations.

Cannabis consistently improves quality of life measures in Crohn's patients across multiple studies. The Naftali trials both showed significant quality of life improvements. Patient surveys from Israel, Canada, and the United States consistently report that cannabis-using IBD patients rate their quality of life higher than before starting cannabis.

The specific domains where cannabis helps most include pain management, appetite restoration, sleep quality, and anxiety reduction. These are all areas where conventional IBD treatments have limited efficacy. Biologics and immunomodulators target inflammation but do little for the associated symptoms that make life with Crohn's difficult.

From a patient perspective, feeling significantly better, even if endoscopic appearances have not changed, is not trivial. Quality of life matters. The key is ensuring that improved quality of life does not lead to complacency about ongoing inflammation management.

Why Gastroenterologists Are Cautious

Most gastroenterologists adopt a cautious stance toward cannabis for Crohn's disease, even though many acknowledge that their patients use it and report benefit. Their concerns center on several points.

The symptom masking problem is the primary concern. Gastroenterologists have spent decades moving the field toward objective disease monitoring and mucosal healing as treatment targets. A treatment that makes patients feel better without achieving these targets, while potentially reducing adherence to treatments that do, runs counter to this paradigm shift.

Drug interactions are a consideration. Both THC and CBD are metabolized by hepatic cytochrome P450 enzymes. CBD in particular inhibits CYP3A4, which metabolizes several medications used in IBD, including corticosteroids and some immunomodulators. The clinical significance of these interactions at typical cannabis doses is not well-characterized.

Smoking is a known risk factor for Crohn's disease flares and complications. Patients who smoke cannabis may be exposing their already vulnerable GI tract to combustion byproducts. Gastroenterologists who counsel against smoking cannabis for Crohn's are making an evidence-based recommendation. Non-smoked delivery methods (oils, capsules, vaporization) avoid this concern.

The lack of product standardization makes it difficult for gastroenterologists to provide specific dosing guidance. Unlike prescribing a biologic at a defined dose, recommending cannabis means the patient will encounter a variable marketplace with inconsistent products.

Practical Guidance for IBD Patients

For Crohn's patients who want to try cannabis as an adjunct to their existing treatment, the following principles apply.

Do not stop your prescribed medications. This cannot be emphasized enough. If you are on a biologic, immunomodulator, or other disease-modifying therapy, continue it. Cannabis may help with symptoms, but it has not been shown to control the underlying disease.

Choose non-smoked delivery methods. Oils, capsules, tinctures, and vaporization are all preferable to smoking for IBD patients. Smoking introduces combustion byproducts and is associated with worse Crohn's outcomes.

Start with CBD-dominant products. Begin with 10 to 25 mg CBD twice daily. After two weeks, add 2.5 mg THC if additional symptom relief is needed. Titrate slowly.

Continue objective monitoring. Fecal calprotectin levels, CRP, and scheduled endoscopies should continue on the same schedule recommended by your gastroenterologist, regardless of how well you feel. Feeling better is not the same as being in remission.

Report cannabis use to your GI team. Many gastroenterologists are more receptive to these conversations than patients expect. Transparency allows your care team to monitor for interactions and adjust treatment plans appropriately.

The Bottom Line

Cannabis provides meaningful symptom relief and quality of life improvements for many Crohn's disease patients. The Naftali trials establish this with reasonable confidence. What cannabis does not do, based on current evidence, is achieve mucosal healing or replace disease-modifying therapy.

This makes cannabis a legitimate adjunct treatment for Crohn's, not a standalone therapy. Patients who use cannabis to feel better while maintaining their prescribed medications and continuing objective disease monitoring are making a reasonable, evidence-informed choice. Patients who use cannabis as a reason to stop biologics or skip follow-up are taking a risk that the evidence does not support.

The distinction between symptom relief and disease modification is not unique to cannabis. Many treatments that patients find helpful for Crohn's, including dietary modifications, stress management, and even some medications, primarily affect symptoms rather than the underlying inflammation. Cannabis is in this category, and knowing where it sits allows patients and their doctors to use it wisely.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.

The Bottom Line

Evidence review of cannabis for Crohn's disease covering Naftali trials, symptom relief vs mucosal healing, anti-inflammatory mechanisms, CBD vs THC, steroid-sparing potential, and gastroenterologist perspective. Naftali 2013 RCT: 21 patients, 8 weeks; 10/11 clinical response vs 4/10 placebo; 5/11 complete remission; 3 patients discontinued steroids. Naftali 2021 RCT: 56 patients, cannabis oil (THC+CBD); significant improvement in symptoms, QoL, CDAI scores vs placebo; BUT no significant improvement in endoscopic mucosal healing. Critical distinction: symptom relief without mucosal healing = patients feel better but inflammation continues → progressive bowel damage, strictures, fistulas; risk of medication non-adherence; objective monitoring (calprotectin, CRP, endoscopy) must continue. Anti-inflammatory mechanisms: CB2 dense on gut wall immune cells; reduces TNF-alpha, IL-1beta, IL-6; CB1/CB2 agonists reduce colitis in animal models; CBD shows promise via CB2/PPARgamma/adenosine — but preclinical effects did not translate to endoscopic improvement in Naftali 2021. CBD alone: Naftali 2017 trial negative (criticized for low dose 10mg BID). Steroid-sparing: 3 patients in Naftali 2013 discontinued steroids; clinically valuable even without mucosal healing. Smoking risk: smoking = known Crohn's flare risk factor; non-smoked routes essential. Drug interactions: CBD inhibits CYP3A4 → may affect corticosteroid/immunomodulator metabolism.

Frequently Asked Questions

Does cannabis help Crohn's disease?

Cannabis significantly improves Crohn's symptoms and quality of life but does not achieve mucosal healing. The Naftali 2013 RCT found 10/11 patients responded to cannabis versus 4/10 placebo, with 5/11 achieving complete remission. The larger Naftali 2021 RCT confirmed symptom improvement and better CDAI scores, but endoscopic assessment showed no significant mucosal healing improvement. Cannabis helps patients feel better without resolving the underlying inflammation that drives disease progression.

Why is the difference between symptom relief and mucosal healing important?

Because uncontrolled Crohn's inflammation causes progressive bowel damage — strictures, fistulas, abscesses — even when symptoms are controlled. Patients who achieve mucosal healing have lower rates of hospitalization, surgery, and complications. If cannabis makes patients feel well without addressing inflammation, they may reduce adherence to biologics or immunomodulators that actually prevent bowel damage. Objective monitoring (fecal calprotectin, CRP, endoscopy) must continue regardless of how patients feel.

Can cannabis replace my Crohn's medication?

No. Cannabis has not been shown to control the underlying disease. If you are on a biologic, immunomodulator, or other disease-modifying therapy, continue it. Cannabis may be a legitimate adjunct for symptom relief — improving pain, appetite, sleep, and quality of life — but it should not replace therapies that achieve mucosal healing and prevent disease progression. Patients who stop biologics because cannabis makes them feel better are taking a risk the evidence does not support.

Can cannabis reduce steroid use in Crohn's?

Preliminary evidence suggests steroid-sparing potential. In the Naftali 2013 trial, 3 of 11 cannabis-treated patients discontinued corticosteroids. This is clinically meaningful because long-term steroids cause osteoporosis, diabetes, adrenal suppression, and immunosuppression. If cannabis can bridge patients through flares with reduced steroid exposure while transitioning to steroid-sparing biologics, this alone would be valuable. However, no dedicated trial has tested this steroid-sparing hypothesis.

Should I smoke or use edibles for Crohn's?

Non-smoked delivery methods are strongly recommended. Smoking is a known risk factor for Crohn's disease flares and complications — combustion byproducts expose an already vulnerable GI tract to additional damage. Oils, capsules, tinctures, and vaporization are all preferable. Start with CBD-dominant products (10-25 mg CBD twice daily), adding 2.5 mg THC if additional symptom relief is needed. Report your cannabis use to your GI team so treatment can be monitored appropriately.

Does CBD alone help Crohn's disease?

The evidence is weak. A clinical trial of CBD alone for Crohn's (Naftali 2017) did not show significant benefit, though it has been criticized for using a potentially insufficient dose (10 mg CBD twice daily). In preclinical models, CBD is at least as effective as THC for reducing gut inflammation through CB2, PPARgamma, and adenosine mechanisms. The combination of THC and CBD appears more effective than either alone for Crohn's symptom management, based on the positive Naftali 2021 results using cannabis oil containing both.